revenueplatform

386 results found.

Top Stocks matching your search for "revenue platform"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
AVXL

Anavex Life Sciences Corporation

-22.55%

$11.75 - $9.10

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Feb, 24, 2023

we have a drug, even many drugs, good for so many ... See more

Jan, 13, 2023

$HTGM A penny with cash and increasing revenue.

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
XERS

Xeris Biopharma Holdings Inc

15.52%

$1.16 - $1.34

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 17, 2023

Two other drugs, each growing revenue steadily.

Mar, 13, 2023

That said, I fully expect continuing script and r... See more

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
FSR

Fisker Inc

-28.83%

$8.15 - $5.80

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 21, 2023

$FSR shows a strong growth in Revenue.

Mar, 21, 2023

Close to generating revenue is only positive

AVXL

Anavex Life Sciences Corporation

-22.55%

$11.75 - $9.10

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Feb, 24, 2023

we have a drug, even many drugs, good for so many indications, to become a giant pharma, we are about to get billions in revenues.

Jan, 13, 2023

$HTGM A penny with cash and increasing revenue.

Jan, 3, 2023

Revenue will pour in.

Dec, 6, 2022

As investors digest the revenue potential, either via approval for RETT, or partnership for AD and PD, the stock price will rise accordingly.

Nov, 29, 2022

$PDD closed 12.62% higher on Monday after the company reported a 65% year-over-year growth in its third-quarter revenue.

XERS

Xeris Biopharma Holdings Inc

15.52%

$1.16 - $1.34

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 17, 2023

Two other drugs, each growing revenue steadily.

Mar, 13, 2023

That said, I fully expect continuing script and revenue growth, upcoming cashflow breakeven and some nice juicy licensing deals to resolve that in the months ahead.

Mar, 3, 2023

Two (2) other drugs, each growing revenue steadily.

Mar, 3, 2023

Two (2) other drugs, each growing revenue steadily.

Mar, 3, 2023

Two (2) other drugs, each growing revenue steadily.

Mar, 3, 2023

Two (2) other drugs, each growing revenue steadily.

Mar, 3, 2023

Two (2) other drugs, each growing revenue steadily.

Mar, 3, 2023

Two (2) other drugs, each growing revenue steadily.

Mar, 3, 2023

Two (2) other drugs, each growing revenue steadily.

Feb, 24, 2023

There is so much good news here, growing revenue, a stable base, conservative management, and connections to big pharma.

FSR

Fisker Inc

-28.83%

$8.15 - $5.80

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 21, 2023

$FSR shows a strong growth in Revenue.

Mar, 21, 2023

Close to generating revenue is only positive

Mar, 21, 2023

$FSR Easy buy before revenue.

Mar, 20, 2023

$FSR shows a strong growth in Revenue.

Mar, 20, 2023

Looking at the last year, $FSR shows a very strong growth in Revenue.

Mar, 20, 2023

Looking at the last year, $FSR shows a very strong growth in Revenue.

Mar, 19, 2023

Revenue is expected to show an annual growth rate (CAGR 2023-2027) of 17.02%, resulting in a projected market volume of US$858.00bn by 2027. 🔥🍺

Mar, 18, 2023

$FSR: The Revenue has grown by 232.04% in the past year.

Mar, 18, 2023

$FSR: The Revenue has grown by 232.04% in the past year.

Mar, 17, 2023

Revenue and a profitable ocean program is coming.